B
CGON icon

Braidwell’s CG Oncology CGON Stock Holding History

Braidwell’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-984,783
Closed -$66.7M – 90
2026
Q1 		$66.7M Sell
984,783
-885,788
-47% -$50.2M 2.22% 14
2025
Q4 		$77.7M Sell
1,870,571
-1,412,746
-43% -$58.5M 2.48% 10
2025
Q3 		$132M Hold
3,283,317
– – 3.92% 5
2025
Q2 		$85.4M Hold
3,283,317
– – 2.92% 14
2025
Q1 		$80.4M Hold
3,283,317
– – 2.83% 12
2024
Q4 		$94.2M Buy
3,283,317
+112,442
+4% +$3.85M 2.79% 10
2024
Q3 		$120M Sell
3,170,875
-138,632
-4% -$4.86M 3.39% 4
2024
Q2 		$104M Buy
3,309,507
+2,179,272
+193% +$75.5M 3.28% 6
2024
Q1 		$49.6M Buy
+1,130,235
New +$46.2M 1.6% 26

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Braidwell's CGON Position: Q2 2026 in Review

Braidwell sold out of CG Oncology (CGON) in Q2 2026, closing a stake of 984,783 shares — an estimated $66.7M sold.

Braidwell first reported a position in CGON in Q1 2024 and held it in 9 quarters. The position peaked at $132M in Q3 2025. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • Braidwell reported no remaining CG Oncology position as of Q2 2026 after selling out during the quarter.
  • Braidwell sold 984,783 CG Oncology shares in Q2 2026, an estimated $66.7M.
  • Braidwell first reported a position in CG Oncology in Q1 2024 and held it in 9 quarters.
  • Braidwell's CG Oncology position peaked at $132M in Q3 2025.
  • 227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Braidwell's 13F filing for Q2 2026, filed 14 Aug 2026.